195-OR: Safety and Performance of the Tandem T:slim X2 with Control-IQ Automated Insulin Delivery System in Preschoolers, Age 2-6 Years Old

Abstract

Glycemic control is particularly challenging for young children with T1DM. We studied the Tandem Control-IQ AP system (CIQ) in children ages 2-5.9 years old during 48hr of supervised outpatient hotel/Airbnb use (SH) followed by 3 days of at home use (H). A minimum of 48hr Tandem standard pump therapy at home (B) preceded the SH phase. Meals and snacks were chosen by parents, without restrictions, and boluses were estimated per parents’ routine. While on closed-loop, all participants were remotely monitored by study staff. There were at least 30 minutes of exercise each day of SH phase. Twelve participants with >3 months of T1D, mean age 4.7±1y, A1C 7.3±0.8%, weight 19.3±3.1kg were enrolled at 3 sites. All were using sensor augmented pumps before entry, with or without automation. All participants completed the study with no adverse events. Outcomes are reported below. CIQ improved mean glucose and TIR without an increase in hypoglycemia during the SH phase; at home CIQ improved all hypoglycemia outcomes as well as TIR, with a tendency towards a better mean glucose. All overnight outcomes were further improved. The Tandem Control IQ system was safe and significantly improved glycemic control in these young children in both the supervised hotel/Airbnb and the home setting. Disclosure L. Ekhlaspour: None. G.P. Forlenza: Advisory Panel; Self; Medtronic. Consultant; Self; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. Research Support; Self; Abbott, Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. M. Schoelwer: Research Support; Self; Tandem Diabetes Care. M.D. DeBoer: Research Support; Self; Tandem Diabetes Care. L. Hsu: Stock/Shareholder; Self; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. R.S. Kingman: None. E. Boranian: Other Relationship; Self; American Diabetes Association. E. Emory: None. R. Wadwa: Advisory Panel; Self; Eli Lilly and Company, Medtronic. Research Support; Self; Dexcom, Inc., Eli Lilly and Company, MannKind Corporation, Medtronic, Novo Nordisk Inc., Tandem Diabetes Care. B.A. Buckingham: Advisory Panel; Self; ConvaTec Inc., Medtronic. Research Support; Self; Beta Bionics, Inc., Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. M.D. Breton: Research Support; Self; Dexcom, Inc., Novo Nordisk A/S, Sanofi, Tandem Diabetes Care. Speaker’s Bureau; Self; Dexcom, Inc., Tandem Diabetes Care. Funding Tandem Diabetes Care